Literature DB >> 18498236

Antimicrobial lock solutions for the prevention of infections associated with intravascular catheters in patients undergoing hemodialysis: systematic review and meta-analysis of randomized, controlled trials.

Dafna Yahav1, Benaya Rozen-Zvi, Anat Gafter-Gvili, Leonard Leibovici, Uzi Gafter, Mical Paul.   

Abstract

BACKGROUND: Prevention of catheter-related bloodstream infections in patients undergoing hemodialysis by use of antimicrobial catheter lock solutions has been examined in several trials, but no consensus is available for clinical practice.
METHODS: A systematic review and meta-analysis were performed of randomized controlled trials that compared single or combination antimicrobial catheter lock solutions with heparin or another antimicrobial for the prevention of infections in patients undergoing hemodialysis. The primary outcomes assessed were bloodstream infections, catheter-related bloodstream infections, and the need for catheter removal. Relative risks with 95% confidence intervals (CIs) for individual trials were pooled.
RESULTS: Eleven trials (924 patients) that assessed antibiotic catheter lock solutions and 5 trials (661 patients)that assessed non antibiotic antimicrobial catheter lock solutions met inclusion criteria. None of the trials assessed all bloodstream infections. Antibiotic catheter lock solutions significantly reduced catheter-related bloodstream infections (relative risk, 0.44; 95% CI, 0.38-0.50). Significant heterogeneity for this outcome could be explained by smaller effect estimates in larger trials that reported adequate randomization methods (relative risk, 0.60; 95%CI, 0.54-0.67). Efficacy was higher when additional preventive measures were used and to prevent the first episode of catheter-related bloodstream infection. Catheter removal rates were significantly reduced (relative risk, 0.35;95% CI, 0.23-0.55). Resistance development was documented in a single patient. Data concerning nonantibiotic antimicrobial lock solutions were limited and heterogeneous. High-quality trials that used additional preventive measures showed a significant reduction in catheter-related bloodstream infections (relative risk, 0.25; 95% CI,0.13-0.50).
CONCLUSIONS: Antibiotic catheter lock solutions reduce catheter-related bloodstream infections, with a number needed to treat of 4 patients (95% CI, 4-5), and catheter removal rates in patients undergoing hemodialysis. The use of antibiotic catheter lock solutions should be considered in routine clinical practice in conjunction with other prevention modalities.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18498236     DOI: 10.1086/588667

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  53 in total

1.  Central venous catheter repair is associated with an increased risk of bacteremia and central line-associated bloodstream infection in pediatric patients.

Authors:  Ingrid S Lundgren; Chuan Zhou; Frances R Malone; Nancy G McAfee; Soren Gantt; Danielle M Zerr
Journal:  Pediatr Infect Dis J       Date:  2012-04       Impact factor: 2.129

2.  Stability of trisodium citrate and gentamicin solution for catheter locks after storage in plastic syringes at room temperature.

Authors:  Dennis Cote; Charmaine E Lok; Marisa Battistella; Lavern Vercaigne
Journal:  Can J Hosp Pharm       Date:  2010-07

Review 3.  Novel approaches to the diagnosis, prevention, and treatment of medical device-associated infections.

Authors:  Paschalis Vergidis; Robin Patel
Journal:  Infect Dis Clin North Am       Date:  2012-03       Impact factor: 5.982

4.  Dialysis: vascular access: not enough light at the end of the tunnel?

Authors:  Raymond Vanholder; Francis Verbeke; Wim Van Biesen
Journal:  Nat Rev Nephrol       Date:  2009-10       Impact factor: 28.314

5.  Guidelines for the prevention of intravascular catheter-related infections.

Authors:  Naomi P O'Grady; Mary Alexander; Lillian A Burns; E Patchen Dellinger; Jeffrey Garland; Stephen O Heard; Pamela A Lipsett; Henry Masur; Leonard A Mermel; Michele L Pearson; Issam I Raad; Adrienne G Randolph; Mark E Rupp; Sanjay Saint
Journal:  Clin Infect Dis       Date:  2011-04-01       Impact factor: 9.079

6.  Quasi-experimental study of sodium citrate locks and the risk of acute hemodialysis catheter infection among critically ill patients.

Authors:  Jean-Jacques Parienti; Stéphanie Deryckère; Bruno Mégarbane; Xavier Valette; Amélie Seguin; Bertrand Sauneuf; Jean-Paul Mira; Bertrand Souweine; Vincent Cattoir; Cédric Daubin; Damien du Cheyron
Journal:  Antimicrob Agents Chemother       Date:  2014-06-30       Impact factor: 5.191

7.  Comparative effectiveness of 30 % trisodium citrate and heparin lock solution in preventing infection and dysfunction of hemodialysis catheters: a randomized controlled trial (CITRIM trial).

Authors:  Franklin Correa Barcellos; Bruno Pereira Nunes; Luciana Jorge Valle; Thiago Lopes; Bianca Orlando; Cintia Scherer; Marcia Nunes; Gabriela Araújo Duarte; Maristela Böhlke
Journal:  Infection       Date:  2016-08-29       Impact factor: 3.553

8.  Adjunctive management of central line-associated bloodstream infections with 70% ethanol-lock therapy.

Authors:  David W Kubiak; Erin T Gilmore; Mary W Buckley; Robert Lynch; Francisco M Marty; Sophia Koo
Journal:  J Antimicrob Chemother       Date:  2014-02-12       Impact factor: 5.790

9.  Guidelines for the prevention of intravascular catheter-related infections: recommendations relevant to interventional radiology for venous catheter placement and maintenance.

Authors:  Donald L Miller; Naomi P O'Grady
Journal:  J Vasc Interv Radiol       Date:  2012-08       Impact factor: 3.464

10.  Rationale and design of the HEALTHY-CATH trial: a randomised controlled trial of Heparin versus EthAnol Lock THerapY for the prevention of Catheter Associated infecTion in Haemodialysis patients.

Authors:  Jennifer K Broom; Stacey O'Shea; Sridevi Govindarajulu; E Geoffrey Playford; Carmel M Hawley; Nicole M Isbel; Scott B Campbell; David W Mudge; Sally Carpenter; Barbara C Johnson; Neil P Underwood; David W Johnson
Journal:  BMC Nephrol       Date:  2009-08-20       Impact factor: 2.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.